Zhong Guo Xin Wen Wang·2025-10-24 13:10Core Insights - He Yuan Bio, a pioneer in "rice-based hematopoiesis" innovative drugs, is set to debut on the Sci-Tech Innovation Board, marking it as the first incremental enterprise in the Sci-Tech Growth Layer [1] - The Sci-Tech Growth Layer currently includes 13 innovative pharmaceutical companies with a total market capitalization of nearly 500 billion yuan, which have collectively facilitated the approval of 25 new drugs since their listing [1] - The establishment of the fifth set of listing standards on the Sci-Tech Board has enabled unprofitable companies to issue shares, significantly boosting the innovative drug sector and attracting substantial investment, with cumulative financing exceeding 1 trillion yuan since 2019 [1][2] Company Performance - The innovative pharmaceutical companies are transitioning from R&D investment phases to commercial revenue generation, with a projected total revenue of 31.9 billion yuan in 2024, reflecting a year-on-year growth rate of 54.39% [2] - These companies have achieved an average annual compound growth rate of 52.33% in revenue since 2019, significantly outpacing the sector's average growth [2] R&D Achievements - A total of 20 new drugs classified as "global new" have been launched, with 10 innovative drugs recognized as "breakthrough therapies" by the National Medical Products Administration [3] - Four original innovative drugs from Chinese companies, including BeiGene and Junshi Biosciences, have received FDA approval for the U.S. market, highlighting the international recognition of these firms [3] - The companies have engaged in potential overseas transactions totaling nearly 5 billion USD this year, indicating strong international market confidence in the innovative drug capabilities of the Sci-Tech Growth Layer [3]